Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

Voice of Healthcare
vohnetwork.com > news > global > sidra-medicine-to-host-pediatric-neuroscience-conference-2026-in-doha

Sidra Medicine to host Pediatric Neuroscience Conference 2026

3+ day, 9+ hour ago   (23+ words) in Doha vohnetwork.com The hybrid conference will offer 16.25 CPD hours and virtual access worldwide...

Voice of Healthcare
vohnetwork.com > news > global > stamina-lifestyle-program-improves-quality-of-life-in-men-on-prostate-cancer-adt

Prostate Cancer STAMINA Program Cuts Treatment Side Effects

3+ day, 6+ hour ago   (20+ words) vohnetwork.com 700 men at 15 NHS facilities joined the 12-month STAMINA trial...

Voice of Healthcare
vohnetwork.com > news > policy > piyush-goyal-calls-for-greater-investment-in-clinical-trials-and-r-and-d

Goyal Calls for More Pharma Clinical Trials

5+ day, 8+ hour ago   (50+ words) Voice of Healthcare Expert highlights the importance of personalised physiotherapy in restoring mobility and confidence on World Physiotherapy Day Piyush Goyal Calls for Greater Investment in Clinical Trials and R&D Govt Hospitals Launch Patient Navigator System to Ease Queues…...

Voice of Healthcare
vohnetwork.com > news > precision-medicine > enhertu-plus-pertuzumab-approved-in-eu-for-first-line-her2-positive-metastatic-breast-cancer

Enhertu Plus Pertuzumab Approved in EU

1+ week, 4+ day ago   (42+ words) for First-Line HER2-Positive Metastatic Breast Cancer Voice of Healthcare The first new first-line regimen in more than a decade reduces the risk of disease progression or death by 44%, with median progression-free survival reaching 40.7 months....

Voice of Healthcare
vohnetwork.com > news > precision-medicine > glp-1-studies-suggest-benefits-may-extend-to-infectious-diseases

GLP-1 Drugs Linked to Lower Infection Risk

1+ week, 5+ day ago   (33+ words) Voice of Healthcare Recent studies link GLP-1 receptor agonists with lower risks of tuberculosis, serious infections, infection-related hospitalisation and mortality in people with type 2 diabetes....

Voice of Healthcare
vohnetwork.com > news > diagnostics > neuberg-diagnostics-strengthens-north-india-footprint-through-strategic-partnership-with-mahajan-imaging-and-labs

Neuberg Diagnostics Partners with Mahajan Imaging

1+ week, 6+ day ago   (24+ words) Voice of Healthcare Partnership accelerates expansion of pathology and integrated diagnostics capabilities across seven states of North India...

Google News
vohnetwork.com > news > precision-medicine > flatiron-health-expands-nsclc-panoramic-dataset-with-comprehensive-biomarker-model

Flatiron Expands NSCLC Biomarker Dataset

2+ week, 4+ day ago   (32+ words) Flatiron Health Expands NSCLC Panoramic Dataset With Comprehensive Biomarker Model Voice of Healthcare AI-extracted biomarker data across 17+ markers and 345,000+ patients expands precision medicine research across the lung cancer continuum...

Voice of Healthcare
vohnetwork.com > news > pharma > beone-medicines-gets-fda-approval-for-tevimbra-based-regimen-in-first-line-her2-plus-gea

BeOne Medicines Gets FDA Nod for TEVIMBRA

2+ week, 4+ day ago   (10+ words) Voice of Healthcare...

Voice of Healthcare
vohnetwork.com > news > precision-medicine > pillar-biosciences-lc-scrum-asia-and-lsi-medience-partner-on-lung-cancer-liquid-biopsy-screening

Pillar Biosciences Partners on Lung Cancer Screening

3+ week, 3+ day ago   (32+ words) Pillar Biosciences, LC-SCRUM-Asia and LSI Medience Partner on Lung Cancer Liquid Biopsy Screening Voice of Healthcare oncoReveal® Essential+ validated for cfDNA and cfRNA screening, with testing planned to begin in August 2026...

Google News
vohnetwork.com > news > precision-medicine > amoydx-pan-lung-cancer-pcr-panel-approved-in-japan-as-trastuzumab-deruxtecan-companion-diagnostic

AmoyDx Panel Approved in Japan for Lung Cancer | Voice of Healthcare

3+ week, 5+ day ago   (15+ words) AmoyDx Pan Lung Cancer PCR Panel Approved in Japan as Trastuzumab Deruxtecan Companion Diagnostic vohnetwork.com...